Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.78 |
| ▸ | TP53 | P04637 | 1/20 | 0.78 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.54 |
| ▸ | RECQL | P46063 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | F2 | P00734 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.44 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.44 |
| ▸ | ESR1 | P03372 | 1/20 | 0.43 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | PRKCA | P17252 | 1/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | SRC | P12931 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL341403 | 1.00 | TSHR (0.78) | TSHRTP53CYP2D6RECQLLMNA | |
| SCHEMBL2331470 | 1.00 | TSHR (0.78) | TSHRTP53CYP2D6RECQLLMNA | |
| SCHEMBL23266974 | 1.00 | TSHR (0.78) | TSHRTP53CYP2D6RECQLLMNA | |
| Water SCHEMBL10705613 | 0.98 | TSHR (0.75) | TSHRTP53CYP2D6RECQLLMNA | |
| Cadaverine Tartrate SCHEMBL16541102 | 0.92 | TSHR (0.85) | TSHRTP53CYP2D6RECQLLMNA | |
| SCHEMBL4190179 | 0.92 | TSHR (0.71) | TSHRTP53CYP2D6RECQLLMNA | |
| SCHEMBL3709855 | 0.92 | TSHR (0.71) | TSHRTP53CYP2D6RECQLLMNA | |
| SCHEMBL670257 | 0.88 | TSHR (1.00) | TSHRTP53CYP2D6RECQLLMNA | |
| SCHEMBL11886503 | 0.88 | TSHR (1.00) | TSHRTP53CYP2D6RECQLLMNA | |
| SCHEMBL223030 | 0.88 | TSHR (1.00) | TSHRTP53CYP2D6RECQLLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012131710-A2 | NOVEL PROCESS FOR THE SYNTHESIS OF INDOLINE DERIVATIVES | PANACEA BIOTEC LTD (IN) | 2012-10-04 | — | — | WO | claimed |
| WO-2011158257-A1 | PREPARATION PROCESS OF FESOTERODINE AND INTERMEDIATES | PANACEA BIOTEC LTD (IN) | 2011-12-22 | — | — | WO | claimed |
| EP-1341762-A1 | PROCESS FOR RESOLVING RACEMIC MIXTURES OF PIPERIDINE DERIVATIVES | ELI LILLY AND COMPANY (US) | 2003-09-10 | — | — | EP | claimed |
| WO-2002068391-A1 | PROCESS FOR RESOLVING RACEMIC MIXTURES OF PIPERIDINE DERIVATIVES | ELI LILLY AND COMPANY (US) | 2002-09-06 | — | — | WO | claimed |
| US-11767317-B1 | Methods of synthesizing enantiopure deuterium-enriched pioglitazone | POXEL SA (FR) | 2023-09-26 | — | — | US | disclosed |
| US-20220144774-A1 | PROCESSES FOR PREPARING (3R,4R)-1-BENZYL-N,4-DIMETHYLPIPERIDIN-3-AMINE OR A SALT THEREOF AND PROCESSES FOR PREPARING TOFACITINIB USING THE SAME | YUHAN CORPORATION (KR) | 2022-05-12 | — | — | US | disclosed |
| US-11319313-B2 | Crystalline forms of deuterium-enriched pioglitazone | POXEL SA (FR) | 2022-05-03 | — | — | US | disclosed |
| US-20210403464-A1 | CRYSTALLINE FORMS OF DEUTERIUM-ENRICHED PIOGLITAZONE | POXEL SA (FR) | 2021-12-30 | — | — | US | disclosed |
| EP-2574188-A1 | NEW PROCESS FOR THE PREPARATION OF ARYL SUBSTITUTED OLEFINIC AMINES | Targacept, Inc. (US) | 2013-04-03 | — | — | EP | disclosed |
| CN-102725272-A | Synthesis of substituted pyrazoline carboxamidine derivatives | ABBOTT HEALTHCARE PRODUCTS BV | 2012-10-10 | — | — | CN | disclosed |
| WO-2012131710-A2 | NOVEL PROCESS FOR THE SYNTHESIS OF INDOLINE DERIVATIVES | PANACEA BIOTEC LTD (IN) | 2012-10-04 | — | — | WO | disclosed |
| WO-2012098461-A1 | FUSED AMINODIHYDROTHIAZINE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-07-26 | — | — | WO | disclosed |
| EP-0729648-A4 | STABILISED ELECTROLYTE SOLUTIONS, METHODS OF PREPARATION THEREOF AND REDOX CELLS AND BATTERIES CONTAINING STABILISED ELECTROLYTE SOLUTIONS | UNISEARCH LTD (AU) | 1997-01-02 | — | — | EP | disclosed |
| WO-1996031478-A1 | TRICYCLIC COMPOUNDS USEFUL FOR INHIBITION OF G-PROTEIN FUNCTION AND FOR TREATMENT OF PROLIFERATIVE DISEASES | SCHERING CORPORATION (US) | 1996-10-10 | — | — | WO | disclosed |
| US-5554620-A | Substituted 6,11-ethano-6,11-dihydrobenzo[b] quinolizinium salts and compositions and methods of use thereof | STERLING WINTHROP INC. (US) | 1996-09-10 | — | — | US | disclosed |
| EP-0729648-A1 | STABILISED ELECTROLYTE SOLUTIONS, METHODS OF PREPARATION THEREOF AND REDOX CELLS AND BATTERIES CONTAINING STABILISED ELECTROLYTE SOLUTIONS | UNISEARCH LIMITED (AU) | 1996-09-04 | — | — | EP | disclosed |
| WO-1995032178-A1 | ENANTIOSELECTIVE PREPARATION OF OPTICALLY PURE ALBUTEROL | SEPRACOR, INC. (US) | 1995-11-30 | — | — | WO | disclosed |
| EP-0656359-A1 | Substituted 6,11-ethano-6,11-dihydrobenzo[b]quinolizinium salts and compositionsand methods of use thereof | STERLING WINTHROP INC. (US) | 1995-06-07 | — | — | EP | disclosed |
| WO-1995012219-A1 | STABILISED ELECTROLYTE SOLUTIONS, METHODS OF PREPARATION THEREOF AND REDOX CELLS AND BATTERIES CONTAINING STABILISED ELECTROLYTE SOLUTIONS | UNISEARCH LIMITED (AU) | 1995-05-04 | — | — | WO | disclosed |
| US-5380721-A | Aryl-fused and hetaryl-fused-2,4-diazepine and 2,4-diazocine antiarrhythmic agents | STERLING WINTHROP INC. (US) | 1995-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220144774-A1 | PROCESSES FOR PREPARING (3R,4R)-1-BENZYL-N,4-DIMETHYLPIPERIDIN-3-AMINE OR A SALT THEREOF AND PROCESSES FOR PREPARING TOFACITINIB USING THE SAME | JAK3, JAK1, JAK2 | TSHR 1383/4885TP53 1194/4885CYP2D6 1902/4885 |
| US-11767317-B1 | Methods of synthesizing enantiopure deuterium-enriched pioglitazone | PPARD, GLP1R, DPP4 | TSHR 695/4885TP53 1933/4885CYP2D6 42/4885 |
| US-20210403464-A1 | CRYSTALLINE FORMS OF DEUTERIUM-ENRICHED PIOGLITAZONE | PPARD, PPARA, PPARG | TSHR 570/4885TP53 976/4885CYP2D6 406/4885 |
| US-11319313-B2 | Crystalline forms of deuterium-enriched pioglitazone | PPARD, PPARA, PPARG | TSHR 570/4885TP53 976/4885CYP2D6 406/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.